<DOC>
	<DOCNO>NCT00287066</DOCNO>
	<brief_summary>To assess impact inhalation insulin glucose disposition patient type 1 diabetes</brief_summary>
	<brief_title>A Clinical Trial Assessing Impact Inhaled Insulin Glucose Disposition</brief_title>
	<detailed_description>The study terminate Oct. 28 , 2007 . The protocol undergoing implementation methodological issue major revision qualify trial new trial . Pfizer decide cancel new trial decision withdraw Exubera due lack market performance safety reason .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Diabetes mellitus Type 1 Asthma , COPD Smoking</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2007</verification_date>
</DOC>